Friday, March 18, 2016, 69 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.20 to $47,685,000.00.

Highlighted Stocks Traded by Insiders:

Bio-Techne (TECH) - FREE Research Report

Lucas Roger C, who is Director at Bio-Techne, sold 100 shares at $92.90 on March 18, 2016. Following this transaction, the Director owned 4,415 shares meaning that the stake was reduced by 2.21% with the 100-share transaction.

The shares most recently traded at $94.68, up $1.78, or 1.88% since the insider transaction. Historical insider transactions for Bio-Techne go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Bio-Techne has been 249,400 shares per day over the past 30 days. Bio-Techne has a market cap of $3.5 billion and is part of the health care sector and drugs industry. Shares are up 5.26% year-to-date as of the close of trading on Friday.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic products worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 35.1. Currently, there are 3 analysts who rate Bio-Techne a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TECH - FREE

TheStreet Quant Ratings

rates Bio-Techne as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Bio-Techne Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

East West Bancorp (EWBC) - FREE Research Report

Gouw Julia S, who is President at East West Bancorp, sold 15,810 shares at $33.05 on March 18, 2016. Following this transaction, the President owned 0 shares meaning that the stake was reduced by 100% with the 15,810-share transaction.

Campbell Molly, who is Director at East West Bancorp, sold 2,172 shares at $32.26 on March 18, 2016. Following this transaction, the Director owned 2,159 shares meaning that the stake was reduced by 50.15% with the 2,172-share transaction.

The shares most recently traded at $33.45, up $1.19, or 3.55% since the insider transaction. Historical insider transactions for East West Bancorp go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 35,000
  • 24-Week # shares sold: 195,753

The average volume for East West Bancorp has been 1.4 million shares per day over the past 30 days. East West Bancorp has a market cap of $4.6 billion and is part of the financial sector and banking industry. Shares are down 19.78% year-to-date as of the close of trading on Friday.

East West Bancorp, Inc. operates as the bank holding company for East West Bank that provides a range of personal and commercial banking services to small and medium-sized businesses, business executives, professionals, and other individuals. The stock currently has a dividend yield of 2.48%. The company has a P/E ratio of 12.1. Currently, there are 8 analysts who rate East West Bancorp a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EWBC - FREE

TheStreet Quant Ratings

rates East West Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

East West Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

ClearOne (CLRO) - FREE Research Report

Baldwin Brad, who is Director at ClearOne, sold 20,000 shares at $12.13 on March 18, 2016. Following this transaction, the Director owned 37,468 shares meaning that the stake was reduced by 34.8% with the 20,000-share transaction.

The shares most recently traded at $12.07, down $0.06, or 0.5% since the insider transaction. Historical insider transactions for ClearOne go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 11,718
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 11,718
  • 24-Week # shares sold: 1,000

The average volume for ClearOne has been 8,600 shares per day over the past 30 days. ClearOne has a market cap of $109.9 million and is part of the technology sector and telecommunications industry. Shares are down 6.57% year-to-date as of the close of trading on Friday.

ClearOne, Inc., together with its subsidiaries, designs, develops, and sells conferencing, collaboration, streaming, and digital signage solutions for audio/voice and visual communications in the United States and internationally. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 16.9. Currently, there is 1 analyst who rates ClearOne a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLRO - FREE

TheStreet Quant Ratings

rates ClearOne as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, solid stock price performance and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

ClearOne Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.